Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
Aspire Biopharma (NASDAQ:ASBP) has launched an influencer marketing campaign for its BUZZ BOMB™ sublingual caffeine pre-workout product. The company has partnered with three prominent fitness influencers: Bobby Maximus (UFC fighter and fitness trainer), Brandon "MidWest Kong" Copeland (Brazilian Jiu-jitsu Black Belt), and Mustafa "The Stallion" Khater (professional bodybuilder), who collectively reach nearly 1 million followers.
BUZZ BOMB™ delivers 50mg of caffeine in less than two minutes through sublingual packets, available in four flavors. The product differentiates itself with rapid onset, convenient single-use packets, and precise energy management capabilities. The company reports positive initial launch feedback from fitness professionals and consumers at recent conventions.
Aspire Biopharma (NASDAQ: ASBP) ha avviato una campagna di influencer marketing per il suo prodotto pre-allenamento al caffeina sublinguale BUZZ BOMB™. L'azienda ha stretto collaborazioni con tre influencer fitness di rilievo: Bobby Maximus (lottatore UFC e personal trainer), Brandon "MidWest Kong" Copeland (Black Belt di Brazilian Jiu-jitsu) e Mustafa "The Stallion" Khater (bodybuilder professionista), che insieme raggiungono quasi 1 milione di follower.
BUZZ BOMB™ fornisce 50 mg di caffeina in meno di due minuti tramite bustine sublinguali, disponibili in quattro gusti. Il prodotto si distingue per l'inizio rapido, le pratiche bustine monouso e le capacità di gestione dell'energia precise. L'azienda riferisce feedback iniziali positivi da professionisti del fitness e consumatori intervenuti a recenti fiere.
Aspire Biopharma (NASDAQ: ASBP) ha lanzado una campaña de marketing de influencers para su producto pre-entrenamiento de cafeína sublingual BUZZ BOMB™. La empresa se ha asociado con tres influyentes destacados del fitness: Bobby Maximus (luchador de UFC y entrenador personal), Brandon "MidWest Kong" Copeland (Cinturón negro de Brazilian Jiu-jitsu) y Mustafa "The Stallion" Khater (culturista profesional), que en conjunto alcanzan casi 1 millón de seguidores.
BUZZ BOMB™ entrega 50 mg de cafeína en menos de dos minutos a través de sobres sublinguales, disponibles en cuatro sabores. El producto se distingue por su inicio rápido, prácticos sobres de un solo uso y capacidades precisas de gestión de energía. La empresa reporta retroalimentación inicial positiva de profesionales del fitness y consumidores durante convenciones recientes.
Aspire Biopharma (NASDAQ: ASBP)가 BUZZ BOMB™ 서브링구얼 카페인 프리워크아웃 제품에 대한 인플루언서 마케팅 캠페인을 시작했습니다. 회사는 세 명의 저명한 피트니스 인플루언서와 협력했습니다: Bobby Maximus (UFC 파이터 및 피트니스 트레이너), Brandon "MidWest Kong" Copeland (브라질리안 주짓수 블랙 벨트), 그리고 Mustafa "The Stallion" Khater (프로 보디빌더)로, 이들은 합쳐 약 100만 명의 팔로워를 보유하고 있습니다.
BUZZ BOMB™는 카페인 50mg를 두 분 이내에 서브링구얼 패킷으로 전달하며, 네 가지 맛으로 제공됩니다. 이 제품은 빠른 효과, 1회용 패킷의 편리함, 그리고 정밀한 에너지 관리 기능으로 차별화됩니다. 최근 컨벤션에서 피트니스 전문가와 소비자로부터 긍정적인 초기 피드백이 보고되었습니다.
Aspire Biopharma (NASDAQ: ASBP) a lancé une campagne de marketing d'influence pour son produit BUZZ BOMB™ pré-entraînement à la caféine sublinguale. L'entreprise s'est associée à trois influenceurs fitness de premier plan : Bobby Maximus (combattant UFC et entraîneur personnel), Brandon "MidWest Kong" Copeland (ceinture noire de Brazilian Jiu-jitsu) et Mustafa "The Stallion" Khater (bodybuilder professionnel), qui ensemble atteignent près d'un million de followers.
BUZZ BOMB™ délivre 50 mg de caféine en moins de deux minutes via des sachets sublinguaux, disponibles en quatre saveurs. Le produit se distingue par son démarrage rapide, ses sachets jetables pratiques et ses capacités de gestion d'énergie précises. L'entreprise indique des retours initiaux positifs de la part de professionnels du fitness et de consommateurs lors de récentes conventions.
Aspire Biopharma (NASDAQ: ASBP) hat eine Influencer-Marketing-Kampagne für sein sublinguales BUZZ BOMB™-Pre-Workout mit Koffein gestartet. Das Unternehmen arbeitet mit drei prominenten Fitness-Influencern zusammen: Bobby Maximus (UFC-Kämpfer und Fitnesstrainer), Brandon "MidWest Kong" Copeland (Black Belt im Brazilian Jiu-Jitsu) und Mustafa "The Stallion" Khater (professioneller Bodybuilder), die zusammen fast 1 Million Follower erreichen.
BUZZ BOMB™ liefert 50 mg Koffein in weniger als zwei Minuten über sublinguale Päckchen, erhältlich in vier Geschmacksrichtungen. Das Produkt zeichnet sich durch einen raschen Wirkbeginn, handliche Einzelnutz-Päckchen und präzise Energiemanagement-Funktionen aus. Das Unternehmen berichtet von positivem erstes Feedback von Fitness-Profis und Verbrauchern auf jüngsten Messen.
Aspire Biopharma (NASDAQ: ASBP) أطلقت حملة تسويق عبر المؤثرين لمنتج BUZZ BOMB™ القهوة تحت اللسان قبل التمرين. شركة قامت بالشراكة مع ثلاثة مؤثرين لياقة بدنية بارزين: Bobby Maximus (مقاتل في UFC ومدرب لياقة)، Brandon "MidWest Kong" Copeland (حزام أسود في الجيو-جيتسو البرازيلي)، وMustafa "The Stallion" Khater (بناء عضلي محترف)، الذين يصل إجمالاً إلى ما يقرب من مليون متابع.
BUZZ BOMB™ يوفر 50 ملغ من الكافيين في أقل من دقيقتين من خلال أكياس تحت اللسان، ومتوفرة في أربعة نكهات. يميّز المنتج ببدء التأثير السريع، وأكياس الاستخدام الواحد المريحة، وقدرات إدارة الطاقة الدقيقة. تقارير الشركة عن ردود فعل إيجابية مبدئية من موظفين مدربين ومستهلكين في مؤتمرات حديثة.
Aspire Biopharma (NASDAQ: ASBP) 已推出针对其 BUZZ BOMB™ 舌下咖啡因健身前产品的网红营销活动。公司与三位知名健身网红合作:Bobby Maximus(UFC 战斗员兼健身教练)、Brandon "MidWest Kong" Copeland(巴西柔术黑带)及 Mustafa "The Stallion" Khater(职业健美运动员),他们合计拥有近100万粉丝。
BUZZ BOMB™ 通过舌下包装在 50 mg 咖啡因 的不到两分钟内起效,提供四种口味。该产品以快速起效、方便的一次性包装以及精准的能量管理能力为特色。公司表示在最近的展会上从健身专业人士和消费者那里获得了积极的初步反馈。
- None.
- Early-stage product with unproven market acceptance
- Highly competitive pre-workout supplement market
- Heavy reliance on influencer marketing strategy
BUZZ BOMB™ engages three specialized fitness influencers to grow the brand
The influencers have hundreds of thousands of followers across social platforms
BUZZ BOMB's™ influencers known for their authenticity and ability to create genuine connections with their followers in the fitness and health world
Sublingual delivery of 50mg of caffeine to the user in less than two minutes
BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company's E-commerce website
ESTERO, FL / ACCESS Newswire / September 17, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced it has launched its influencer marketing campaign designed to drive conversion, brand awareness and loyalty for its innovative BUZZ BOMB™ pre-workout product. Featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), BUZZ BOMB™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed for immediate effect.
Kraig Higginson, Interim Chief Executive Officer of Aspire, commented, "We are thrilled to have three well-respected and accomplished athletes collaborating with us to share the benefits of BUZZ BOMB™ with their followers, which total close to 1 million people. BUZZ BOMB™ represents a truly innovative product in the multi-billion-dollar pre-workout space and we are very excited about the initial launch results and feedback from many well-known fitness instructors, athletes, and influencers along with thousands of fitness enthusiasts and consumers who sampled BUZZ BOMB™ at the two major fitness conventions held in August. By partnering with influencers who already have strong, authentic connections with their highly engaged followers, Aspire aims to increase brand credibility and consumer trust while driving faster sales of our BUZZ BOMB™ pre-workout product."
BUZZ BOMB™ Engages Three Specialized Influencers to Grow the Brand
Bobby Maximus is a UFC fighter, Ju Jitsu Masters World Champion and fitness trainer. He has broken multiple power-endurance world records and is recognized as a leading figure in the fitness world. He starred in the recent feature film "Kill Shot" and is a best-selling Men's Health author and a regular contributor to "Men's Health" magazine. For more about Booby Maximus, please visit https://www.bobbymaximus.com/about-2 of follow him on Instagram at https://www.instagram.com/bobbymaximus/?hl=en
Brandon "MidWest Kong" Copeland (pictured above, third to the right) embodies the strength of a champion and the heart of a hero. A Brazilian Jiu-jitsu Black Belt, Copeland dominated the Mixed Martial Arts scene from 2005 to 2014, showcasing tenacity and skill. Initiating the "I Stopped The Bully" campaign in 2011, he became a beacon against bullying, inspiring youth across schools and detention centers. Copeland excelled in the fitness industry, breaking records like bench pressing 225
Mustafa Khater aka "The Stallion":
The Stallion is an internationally ranked competitive male body builder. He has consistently placed in the top 5 Mr. World renowned Mr. Olympia international competition, and for 3 consecutive years he has place in the top 3, an honor only a few have ever achieved. He also placed first in the Mr. California body building competition. In addition to body building competition, Mustafa also is a well-known Trainer, and professional fitness coach including online coaching and training. Mustafa has a large following online of nearly 275,000 dedicated students and fans.
Follow Mustafa Khater on Instagram at https://www.instagram.com/ifbbpro_moose_the_stallion/?hl=en
BUZZ BOMB™ Pre-workout Benefits:
Speed - works nearly immediately (less than 2 minutes) vs. 20-30 minutes
Convenience - easy to use single-use packets vs. mixing and measuring for beverages
Energy management - use as needed to precisely manage caffeine intake (50mg increments)
Single Safe Active Ingredient - well-known benefits and use of caffeine
A clean manageable Energy Boost
Low manufacturing & packaging costs - competitive pricing with high margin potential
Aspire's BUZZ BOMB™ - Delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma delivers supplements to the body rapidly and precisely.
For more information, please visit www.aspirebiolabs.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire